Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with buprenorphine Combines Sandoz expertise in launching…
Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcarePublication, which coincides with World Health Day 2018, outlines plans for expanded competition to…
Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcarePublication, which coincides with World Health Day 2018, outlines plans for expanded competition to…
Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatologyPositive opinion is based on comprehensive clinical and non-clinical data that is expected to …
Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatologyPositive opinion is based on comprehensive clinical and non-clinical data that is expected to …
Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mLGlatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched in the US in June 2015, will offer patients a complete range of…
Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings in Europe and RussiaThe annual, international research undertaken by the Top Employers Institute recognizes leading employers around the worldThi…
Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto, more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1 billion in 2017, USD 615 million in Q4Entresto grew to USD 507…
Collaboration aims to help patients worldwide gain access to a range of high-quality, affordable immunology and oncology biologicsPartnership will be an important part of Sandoz and Biocon strategy to address the next wave of biosimilar opportunitie…
Adalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1]The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab matches the reference biologic medicine in terms of safet…